Cargando…

Changes to International Nonproprietary Names for antibody therapeutics 2017 and beyond: of mice, men and more

Active pharmaceutical substances require an International Nonproprietary Name (INN) assigned by the World Health Organization (WHO) to obtain market authorization as a medicinal product. INNs are selected to represent a unique, generic name for a drug enabling unambiguous identification by stakehold...

Descripción completa

Detalles Bibliográficos
Autores principales:	Parren, Paul W. H. I., Carter, Paul J., Plückthun, Andreas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2017
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5590622/ https://www.ncbi.nlm.nih.gov/pubmed/28621572 http://dx.doi.org/10.1080/19420862.2017.1341029

Ejemplares similares

The INNs and outs of antibody nonproprietary names
por: Jones, Tim D., et al.
Publicado: (2015)

International nonproprietary names for monoclonal antibodies: an evolving nomenclature system
por: Guimaraes Koch, Sofia S., et al.
Publicado: (2022)

Systematic analysis of the varied designs of 819 therapeutic antibodies and Fc fusion proteins assigned international nonproprietary names
por: Wilkinson, Ian, et al.
Publicado: (2022)

Patient Safety in Medication Nomenclature: Orthographic and Semantic Properties of International Nonproprietary Names
por: Bryan, Rachel, et al.
Publicado: (2015)

International Nonproprietary Names (INN) for novel vaccine substances: A matter of safety
por: Robertson, James S., et al.
Publicado: (2022)

The Impact of International Nonproprietary Names Integration on Prescribing Reimbursement Medicines for Arterial Hypertension and Analysis of Medication Errors in Latvia
por: Gavrilova, Anna, et al.
Publicado: (2022)

International nonproprietary names (INN) for pharmaceuticals substances : lists 1-73 of proposed INN and lists 1-35 of recomended INN cumulative list No. 9 = Dénominations communes internationales (DCI) pour les substances pharmaceutiques : listes 1-73 de DCI proposées et listes 1-35 de DCI recommandées liste récapitulative No. 9
Publicado: (1996)

International nonproprietary names (INN) for pharmaceutical substances, : lists 1-65 of proposed INN and lists 1-31 of recommended INN : cumulative list no. 8 = Dénominations communes internationales (DCI) pour les substances pharmaceutiques, listes 1-65 de DCI proposées et listes 1-31 de DCI recommandées : liste récapitulative no. 8.
Publicado: (1992)

International nonproprietary names (INN) for pharmaceutical substances : lists 1-65 of proposed INN and lists 1-31 of recommended INN : cumulative list no. 8 = Dénominations communes internationales (DCI) pour les substances pharmaceutiques : listes 1-65 de DCI proposées et listes 1-31 de DCI recommandées : liste récapitulative no. 8.
Publicado: (1992)

The harmonization of World Health Organization International Nonproprietary Names definitions for cell and cell-based gene therapy substances: when a name is not enough
por: Loizides, Ursula, et al.
Publicado: (2021)

International nonproprietary names (INN) for pharmaceutical substances, 1988 : lists 1-58 of proposed INN and lists 1-27 of recommended INN : cumulative list no. 7 = Dénominations communes internationales (DCI) pour les substances pharmaceutiques, 1988 : listes 1-58 de DCI proposées et listes 1-27 de DCI recommandées : liste récapitulative no. 7.
Publicado: (1988)

International nonproprietary names (INN) for pharmaceutical substances, 1982 : lists 1-47 of proposed INN and lists 1-21 of recommended INN : cumulative list no. 6 = Dénominations communes internationales (DCI) pour les substances pharmaceutiques, 1982 : listes 1-47 de DCI proposées et listes 1-21 de DCI recommandées : liste récapitulative no. 6.
Publicado: (1982)

Nomenclature and Traceability Debate for Biosimilars: Small-Molecule Surrogates Lend Support for Distinguishable Nonproprietary Names
por: Chao, Jingdong, et al.
Publicado: (2015)

Animal- versus in vitro-derived antibodies: avoiding the extremes
por: Bradbury, Andrew R.M., et al.
Publicado: (2021)

Antibodies to watch in 2017
por: Reichert, Janice M.
Publicado: (2016)

The Tragedy of Names
por: Radcliffe, Christopher
Publicado: (2021)

Clinical implications for substandard, nonproprietary medicines in multiple sclerosis: focus on fingolimod
por: Correale, Jorge, et al.
Publicado: (2016)

In the name of the greater good?
por: Kirkwood, K
Publicado: (2010)

Fab-arm exchange: What’s in a name?
por: Schuurman, Janine, et al.
Publicado: (2012)

The Antibody Society’s antibody validation webinar series
por: Voskuil, Jan L.A., et al.
Publicado: (2020)

What's in a name? The case of cyanobacteria
por: Garcia‐Pichel, Ferran, et al.
Publicado: (2019)

Antibody Engineering and Therapeutics Conference: The Annual Meeting of the Antibody Society, December 8–12, 2013, Huntington Beach, CA
por: Almagro, Juan Carlos, et al.
Publicado: (2013)

Mesenchymal Stem Cells: Time to Change the Name!
por: Caplan, Arnold I.
Publicado: (2017)

Beyond prostate, beyond surgery and beyond urology: The “3Bs” of managing non-neurogenic male lower urinary tract symptoms
por: Song, Qixiang, et al.
Publicado: (2019)

Why women have more autoimmune diseases than men: An evolutionary perspective
por: Kronzer, Vanessa L., et al.
Publicado: (2020)

Visible name changes promote inequity for transgender researchers
por: Gaskins, Leo Chan, et al.
Publicado: (2021)

Opening the door to innovation
por: Schuurman, Janine, et al.
Publicado: (2014)

Therapeutic antibodies for infectious diseases
por: Sparrow, Erin, et al.
Publicado: (2017)

Contact tracing following measles exposure on three international flights, Germany, 2017
por: Thole, Sebastian, et al.
Publicado: (2019)

Single-particle cryo-EM: beyond the resolution
por: Armache, Jean-Paul, et al.
Publicado: (2019)

Rethinking the INN system for therapeutic antibodies
por: Pottier, Jérémy, et al.
Publicado: (2016)

Antibody engineering and therapeutics conference: The annual meeting of the antibody society, Huntington Beach, CA, December 7–11, 2014
por: Larrick, James W, et al.
Publicado: (2014)

Therapeutic index improvement of antibody-drug conjugates
por: Gerber, Hans-Peter, et al.
Publicado: (2023)

Antibodies Used to Detect Glaucoma-Associated Myocilin: More or Less Than Meets the Eye?
por: Patterson-Orazem, Athéna C., et al.
Publicado: (2019)

A New Name for Pneumocystis from Humans and New Perspectives on the Host-Pathogen Relationship
por: Stringer, James R., et al.
Publicado: (2002)

The Benefits of Artemisinin Combination Therapy for Malaria Extend Beyond the Individual Patient
por: Garner, Paul, et al.
Publicado: (2005)

More harm than good? The questionable ethics of medical volunteering and international student placements
por: Bauer, Irmgard
Publicado: (2017)

Editorial: Antibody Therapeutics for the Treatment of Filoviral Infection
por: Murin, Charles D., et al.
Publicado: (2022)

Beyond Structure: Defining the Function of the Gut Using Omic Approaches for Rational Design of Personalized Therapeutics
por: Theriot, Casey M.
Publicado: (2018)

Therapeutic potential of AMPA receptor antagonist perampanel against cerebral ischemia: beyond epileptic disorder
por: Suda, Satoshi, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_t0u79m4ol2vivo7r358nc6a4ht